Arovella Therapeutics Ltd has released a press release.
New Analyst Report
Filed with ASX ·
On 6ix: 6ix.com/news/new-analyst-report
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- SUDA Completes Acquisition Of Anti-Cancer Agent
- SUDAs Licensee Submits Marketing Application
- SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent
- SUDA Publishes Amended Shareholder Newsletter
- SUDA Achieves ISO Accreditation
Later from Arovella Therapeutics
- Divestment Of Non-Core Subsidiary
- SUDA Completes Divestment of Subsidiary
- HC Berlin Pharma Update
- SUDA expands dialogue with World Health Organisation
- SUDA announces update on ZolpiMist in USA and Canada
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics